Akil Loli, MD
Interventional Cardiology · Phoenix, AZNPI 1962453803
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (42.8%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Abiomed at 25.0% of the total. Among interventional cardiology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 918 payments — averaging $174.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$40K
- Shockwave Medical, Inc$37K
- Boston Scientific$31K
- Medtronic$14K
- Cvrx, Inc.$14K
- Edwards Lifesciences$8K
- plus $17K from 32 others
Across 53 payments — averaging $6530.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Endotronix, Inc.$221K
- Cvrx, Inc.$52K
- Abbott$52K
- Endologix LLC$11K
- Vifor (international) Ltd.$7K
- Boston Scientific$3K
What the payments were for
- Consulting fees$30,75019%
- Speaking & faculty fees$68,32543%
- Travel & lodging$21,99914%
- Food & beverage$38,53124%
- Education$2150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 221 | $39,934 |
| Shockwave Medical, Inc | 60 | $36,781 |
| Boston Scientific | 91 | $30,633 |
| Medtronic(2 entities) | 146 | $13,905 |
| Cvrx, Inc. | 60 | $13,666 |
| Edwards Lifesciences | 90 | $8,388 |
| Abbott | 116 | $6,499 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 17 | $2,448 |
| Penumbra, Inc. | 10 | $2,116 |
| Atricure, Inc. | 10 | $1,775 |
| Angiodynamics, Inc. | 8 | $535 |
| Biosense Webster, Inc. | 12 | $468 |
| Cardiovascular Systems Inc. | 25 | $308 |
| Philips North America LLC | 3 | $281 |
| AstraZeneca | 3 | $250 |
| ZOLL Circulation Inc | 2 | $232 |
| Amgen | 7 | $219 |
| Biotronik Inc. | 4 | $182 |
| ZOLL Respicardia, Inc. | 2 | $164 |
| Terumo Medical Corporation | 3 | $154 |
| Impulse Dynamics (USA) Inc. | 1 | $153 |
| Inspire Medical Systems, Inc. | 1 | $150 |
| Kestra Medical Technology Services, Inc. | 1 | $150 |
| Johnson & Johnson | 6 | $79 |
| Cardiva Medical, Inc. | 4 | $71 |
| Recor Medical Inc | 1 | $40 |
| Siemens Medical Solutions USA, Inc. | 2 | $36 |
| Imperative Care, Inc | 1 | $30 |
| Teleflex LLC | 1 | $29 |
| Biom'up France SAS | 1 | $26 |
| Gilead | 2 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Bardy Diagnostics, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Novartis | 1 | $14 |
| Pfizer | 1 | $13 |
| Lundbeck LLC | 1 | $12 |
| Itamar Medical Inc | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$36,473
- WATCHMAN Access System$25,750
- Impella$24,104
- Barostim Neo System$12,360
- Micra$9,645
- Edwards SAPIEN 3 Transcatheter Heart Valve$2,593
- LifeVest$1,966
- Indigo System$1,807
- ATRICLIP LAA EXCLUSION SYSTEM$1,726
- Mitra Clip system$1,067
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$1,022
- GENERAL - THERAPIES$978
- WATCHMAN FLX$847
- SAPIEN 3 Ultra RESILIA$719
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$481
- MitraClip$388
- Watchman$380
- CARDIOMEMS$356
- AVEIR$329
- OPTIMIZER$307
How this compares
$159,820 in reported general payments places this provider in the 95th percentile of 223 interventional cardiology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 106 | $140,440 |
| EntrestoSacubitril/Valsartan | 71 | $110,218 |
| XareltoRivaroxaban | 47 | $66,392 |
| Repatha SureclickEvolocumab | 72 | $65,801 |
| OzempicSemaglutide | 28 | $38,863 |
| Praluent PenAlirocumab | 33 | $30,694 |
| BrilintaTicagrelor | 35 | $29,256 |
| FarxigaDapagliflozin Propanediol | 15 | $16,223 |
| Repatha SyringeEvolocumab | 12 | $6,503 |
| Ranolazine ErRanolazine | 34 | $4,037 |
| ClopidogrelClopidogrel Bisulfate | 344 | $3,892 |
| Losartan Potassium | 304 | $3,022 |
| Atorvastatin Calcium | 309 | $2,371 |
| Isosorbide Dinitrate | 44 | $2,351 |
| Rosuvastatin Calcium | 215 | $2,258 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $13 | $140,440106 claims |
| NovartisEntresto | $14 | $110,21871 claims |
| Johnson & JohnsonXarelto | $79 | $66,39247 claims |
| AstraZenecaBrilinta, Farxiga | $250 | $45,47950 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 223 interventional cardiology providers in Arizona.
Other interventional cardiology in Phoenix
- Paul SorajjaPhoenix$1.1M
- Timothy ByrnePhoenix$614K
- Haidar YassinPhoenix$434K
- Nishant GuptaPhoenix$145K
- Richard HeuserPhoenix$68K
- Nezar FallujiPhoenix$50K
- Ahmad JabriPhoenix$39K
- Edward EvansPhoenix$36K
- Basil Al KhatibPhoenix$33K
- Sourabh AggarwalPhoenix$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.